Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Gastroesophageal Reflux Disease Therapeutics Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The gastroesophageal reflux disease therapeutics market has demonstrated robust expansion over recent years. It is projected to increase from $6.08 billion in 2025 to $6.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. The historical development of this market is attributable to the rising prevalence of gerd, the adoption of proton pump inhibitors, heightened awareness regarding digestive health, the growth of hospital pharmacies, and an expanding geriatric population.
The gastroesophageal reflux disease therapeutics market is expected to experience substantial growth over the next few years. It is projected to reach $8.38 billion in 2030, expanding at a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period can be attributed to innovations in drug formulations, the expansion of e-pharmacies, the adoption of telemedicine for gastro care, increasing investment in precision medicine, and the growing demand for minimally invasive therapies. Major trends identified for the forecast period include personalized GERD treatment approaches, the development of novel drug delivery systems, a rising demand for over-the-counter GERD medications, an increased focus on gut health and microbiome regulation, and the integration of remote patient monitoring and telehealth services.
Get A Free Sample Report With In-Depth Market Insights:
Gastroesophageal Reflux Disease Therapeutics Market Growth Factors: What’s Supporting Expansion?
The gastroesophageal reflux disease therapeutics market is experiencing growth driven by the increased embrace of self-medication. This approach involves individuals using drugs or other substances to manage a medical condition without professional consultation. Self-medication is instrumental in improving GERD symptoms by aiding in the identification and avoidance of trigger foods, stress management, and smoking cessation. For instance, in July 2024, the Proprietary Association of Great Britain (PAGB), a UK-based trade association, highlighted that 64 million UK residents experienced at least one self-treatable condition in 2023. The same report indicated a notable increase in GP-advised cases for over-the-counter self-care, which rose from 58% in 2023 to 75% in 2024, while consumer confidence in these medications escalated to 89%, representing an 8-point gain over the previous year. Thus, the growing adoption of self-medication is a primary factor propelling the gastroesophageal reflux disease therapeutics market.
Gastroesophageal Reflux Disease Therapeutics Market Segment Landscape: Which Areas Lead Development?
The gastroesophageal reflux disease therapeutics market covered in this report is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
Subsegments:
1) By Branded: Proton Pump Inhibitors (PPIs), H2-Receptor Antagonists, Antacids, Coating Agents
2) By Generic: Generic Proton Pump Inhibitors (PPIs), Generic H2-Receptor Antagonists, Generic Antacids, Generic Coating Agents
Gastroesophageal Reflux Disease Therapeutics Market Industry Trends: What’s Reshaping Demand?
Leading companies in the gastroesophageal reflux disease therapeutics market are prioritizing the development of innovative solutions, such as wireless pH-capsule reflux testing systems. These wireless pH-capsule reflux testing systems are medical devices specifically designed for the diagnosis and ongoing monitoring of gastroesophageal reflux disease (GERD) and related health conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a US-based company manufacturing medical testing equipment, announced the debut of its alpHaONE system. This system is a wireless pH-capsule reflux testing device precisely engineered to diagnose gastroesophageal reflux disease (GERD). It offers up to 96 hours of data monitoring, ensuring the provision of accurate and reliable data. The alpHaONE presents a distinct solution, featuring an ergonomic and compact design, enlarged buttons that are easy to press, and a fail-safe capsule delivery system intended to safeguard the patient’s oesophagus.
Gastroesophageal Reflux Disease Therapeutics Market Industry Leaders And Competitive Landscape
Major companies operating in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited
View The Full Gastroesophageal Reflux Disease Therapeutics Market Report:
Gastroesophageal Reflux Disease Therapeutics Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
